<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632006</url>
  </required_header>
  <id_info>
    <org_study_id>EHBHKY2015-02-009</org_study_id>
    <nct_id>NCT02632006</nct_id>
  </id_info>
  <brief_title>Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>A Clinical Study of Adoptive Cellular Immunotherapy Using Pluripotent Killer T Cells Expressing Antibodies for Programmed Death 1 (PD-1) in Treating Patients With Advanced Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Military Medical University</source>
  <brief_summary>
    <textblock>
      Objectives:

      The purpose of this study is to evaluate the safety and efficacy of PIK-PD-1 Cells in the
      treatment of advanced Hepatocellular Carcinoma.

      Methods:

      This study designs a novel therapy using PIK-PD-1 cells. 40 patients with advanced
      Hepatocellular Carcinoma will be enrolled. They are randomly divided into dendritic
      cell-precision multiple antigen T cells (DC-PMAT) group and PIK-PD-1 cells group. Both
      DC-PMAT treatment and PIK-PD-1 cells treatment will be performed every 3 weeks with a total
      of three periods. The mail clinical indicators are Progression-Free-Survival and Overall
      Survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 40 patients may be enrolled over a period of 1-2 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 yeas</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>2 yeas</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 yeas</time_frame>
    <description>Quality of life core questionnaire will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Advanced Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>PIK-PD-1 cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PIK-PD-1 cells treatment will be performed every 3 weeks with a total of three periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DC-PMAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DC-PMAT cells treatment will be performed every 3 weeks with a total of three periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PIK-PD-1 cells</intervention_name>
    <description>DC cell suspension (1×10*7 DC+ physiological saline
+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.</description>
    <arm_group_label>PIK-PD-1 cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DC-PMAT</intervention_name>
    <description>DC cell suspension (1×10*7 DC+ physiological saline
+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.</description>
    <arm_group_label>DC-PMAT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Age 20~70 years old, male or female; 2. Barcelona Clinic Liver Cancer(BCLC) C
             stage; no indication for operation, local treatment (Transcatheter Arterial
             Chemoembolization (TACE), percutaneous icro wave coagulation therapy (PMCT),
             percutaneous ethanol injection therapy (PEIT)) and radiation therapy; unable or
             unwilling to receive sorafenib therapy; 3.Child-Pugh score ≤ 9; 4.Eastern Cooperative
             Oncology Group (ECOG) score ≤ 2; 5.Life expectancy＞3 months; 6. white blood cell (WBC)
             &gt; 3 x 10*9/L, Neutrophils &gt; 1 x 10*9/L, lymphocyte &gt; 1 x 10*9/L, hemoglobin ≥8.5g/dl,
             Platelet ≥50×109/L, prothrombin time (PT) no more than 3 seconds, Cr and blood urea
             nitrogen (BUN) less than 3 times of the normal level; 7. Adequate venous access, blood
             cell production without other taboos; 8. Signed informed consent.

        Exclusion Criteria:

          -  1. Immunosuppressive therapy needed with autoimmune disease or organ transplantation
             history； 2. HIV/Syphilis infection; 3. Positive blood culture or imaging evidence
             infection; 4. Other drugs, gene therapy, biological, chemotherapy or radiation therapy
             were used within 1 months.

             5. The history of allergic reactions in cell therapy or cytokine. 6. PD-1 antibodies
             have been used before, or allergies due to PD-1 antibody drugs.

             7. History of interstitial lung disease. 8. History of esophagus varicosis rupture
             haemorrhage. 9. Other serious diseases:the heart,lung, kidney, digestive, nervous,
             mental disorders, immune regulatory diseases, metabolic diseases, infectious diseases,
             Etc.

             10. Pregnant, lactating women, or pregnancy planned at the following 2 years. 11.
             Without signed informed consent. 12. Other researchers considered ones unsuitable for
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qijun Qian, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Eastern Hepatobiliary Surgery Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qijun Qian, PHD</last_name>
    <phone>+86-21-65580677</phone>
    <email>qianqj@sino-gene.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huajun Jin, PHD</last_name>
    <phone>+86-21-81875372</phone>
    <email>hj-jin@Hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200438</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huajun Jin, PHD</last_name>
      <phone>+86-21-81875372</phone>
      <email>hj-jin@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Qijun Qian, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huajun Jin, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xijing Yang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saiqun Lv, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J, Tang ZY. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol. 2006 May;132(5):293-301. Epub 2006 Jan 19.</citation>
    <PMID>16421755</PMID>
  </reference>
  <reference>
    <citation>Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005 Sep-Oct;28(5):496-504.</citation>
    <PMID>16113606</PMID>
  </reference>
  <reference>
    <citation>González-Carmona MA, Märten A, Hoffmann P, Schneider C, Sievers E, Schmidt-Wolf IG, Sauerbruch T, Caselmann WH. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells. Liver Int. 2006 Apr;26(3):369-79.</citation>
    <PMID>16584401</PMID>
  </reference>
  <reference>
    <citation>Yannelli JR, Sturgill J, Foody T, Hirschowitz E. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2005 Mar;47(3):337-50.</citation>
    <PMID>15713517</PMID>
  </reference>
  <reference>
    <citation>Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma. Cancer. 2005 Feb 15;103(4):763-71.</citation>
    <PMID>15637694</PMID>
  </reference>
  <reference>
    <citation>Bellik L, Gerlini G, Parenti A, Ledda F, Pimpinelli N, Neri B, Pantalone D. Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer. Clin Immunol. 2006 Oct;121(1):74-80. Epub 2006 Aug 17.</citation>
    <PMID>16914380</PMID>
  </reference>
  <reference>
    <citation>Babatz J, Röllig C, Löbel B, Folprecht G, Haack M, Günther H, Köhne CH, Ehninger G, Schmitz M, Bornhäuser M. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol Immunother. 2006 Mar;55(3):268-76. Epub 2005 Jul 21.</citation>
    <PMID>16034561</PMID>
  </reference>
  <reference>
    <citation>Fay JW, Palucka AK, Paczesny S, Dhodapkar M, Johnston DA, Burkeholder S, Ueno H, Banchereau J. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother. 2006 Oct;55(10):1209-18. Epub 2005 Dec 6.</citation>
    <PMID>16331519</PMID>
  </reference>
  <reference>
    <citation>Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML, Parente P, Cavicchiolo T, Hopkins W, Jackson H, Dimopoulos N, Tai TY, MacGregor D, Browning J, Svobodova S, Caron D, Maraskovsky E, Old LJ, Chen W, Cebon J. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients. J Immunother. 2006 Sep-Oct;29(5):499-511.</citation>
    <PMID>16971806</PMID>
  </reference>
  <reference>
    <citation>Escobar A, López M, Serrano A, Ramirez M, Pérez C, Aguirre A, González R, Alfaro J, Larrondo M, Fodor M, Ferrada C, Salazar-Onfray F. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005 Dec;142(3):555-68.</citation>
    <PMID>16297169</PMID>
  </reference>
  <reference>
    <citation>Thomas-Kaskel AK, Zeiser R, Jochim R, Robbel C, Schultze-Seemann W, Waller CF, Veelken H. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer. 2006 Nov 15;119(10):2428-34.</citation>
    <PMID>16977630</PMID>
  </reference>
  <reference>
    <citation>Fuessel S, Meye A, Schmitz M, Zastrow S, Linné C, Richter K, Löbel B, Hakenberg OW, Hoelig K, Rieber EP, Wirth MP. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate. 2006 Jun 1;66(8):811-21.</citation>
    <PMID>16482569</PMID>
  </reference>
  <reference>
    <citation>Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol Immunother. 2006 Nov;55(11):1432-42. Epub 2006 Apr 13. Review.</citation>
    <PMID>16612595</PMID>
  </reference>
  <reference>
    <citation>Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. J Immunother. 2005 Nov-Dec;28(6):551-9.</citation>
    <PMID>16224272</PMID>
  </reference>
  <reference>
    <citation>Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother. 2005 Jul;54(7):663-70. Epub 2004 Dec 17.</citation>
    <PMID>15918076</PMID>
  </reference>
  <reference>
    <citation>Ferrari S, Malugani F, Rovati B, Porta C, Riccardi A, Danova M. Flow cytometric analysis of circulating dendritic cell subsets and intracellular cytokine production in advanced breast cancer patients. Oncol Rep. 2005 Jul;14(1):113-20.</citation>
    <PMID>15944777</PMID>
  </reference>
  <reference>
    <citation>Bohnenkamp HR, Coleman J, Burchell JM, Taylor-Papadimitriou J, Noll T. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers. Cell Immunol. 2004 Sep-Oct;231(1-2):112-25. Epub 2005 Feb 8.</citation>
    <PMID>15919376</PMID>
  </reference>
  <reference>
    <citation>Chen W, Chan AS, Dawson AJ, Liang X, Blazar BR, Miller JS. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. Biol Blood Marrow Transplant. 2005 Jan;11(1):23-34.</citation>
    <PMID>15625541</PMID>
  </reference>
  <reference>
    <citation>Triozzi PL, Khurram R, Aldrich WA, Walker MJ, Kim JA, Jaynes S. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer. 2000 Dec 15;89(12):2646-54.</citation>
    <PMID>11135227</PMID>
  </reference>
  <reference>
    <citation>Nestle FO. Dendritic cell vaccination for cancer therapy. Oncogene. 2000 Dec 27;19(56):6673-9. Review. Erratum in: Oncogene 2001 Oct 18;20(47):6970.</citation>
    <PMID>11426654</PMID>
  </reference>
  <reference>
    <citation>Mackensen A, Herbst B, Chen JL, Köhler G, Noppen C, Herr W, Spagnoli GC, Cerundolo V, Lindemann A. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int J Cancer. 2000 May 1;86(3):385-92.</citation>
    <PMID>10760827</PMID>
  </reference>
  <reference>
    <citation>Iinuma T, Homma S, Noda T, Kufe D, Ohno T, Toda G. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest. 2004 May;113(9):1307-17.</citation>
    <PMID>15124022</PMID>
  </reference>
  <reference>
    <citation>Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003 Mar;9(3):998-1008.</citation>
    <PMID>12631598</PMID>
  </reference>
  <reference>
    <citation>Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002 May 20;195(10):1279-88. Erratum in: J Exp Med. 2003 Feb 3;197(3):395..</citation>
    <PMID>12021308</PMID>
  </reference>
  <reference>
    <citation>O'Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, Slater GJ, Kerr BM, Crowe B, Purdie DM, Elliott SL, Ellem KA, Schmidt CW. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003 Jun;52(6):387-95. Epub 2003 Apr 8.</citation>
    <PMID>12682787</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 13, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>December 30, 2015</last_update_submitted>
  <last_update_submitted_qc>December 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PIK-PD-1 Cells</keyword>
  <keyword>dendritic cell-precision multiple antigen T cells</keyword>
  <keyword>advanced hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

